Moltbook has gained a lot of attention since it was created last week, thanks to a lot of wild posts from AI agents that have ...

April 10, 2026 Target Action Date for RP1 in Advanced MelanomaWOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in The Trade Desk Inc (Symbol: TTD), where a total of 69,953 contracts have traded so far, ...

A strange fog envelops the town, sowing fear and chaos. The monster is loose. By Sean T. Collins A good Pennywise murder has several key components. It has to be disgusting, first of all. It has to be ...

Since 2022, OpenAI has been the primary character in the most interesting tech and business story in years. ChatGPT was early, and so was OpenAI’s fundraising. Its models were more capable than ...

In a volatile jobs market upended by AI and a host of other factors, it’s important to recognize employers that go above and beyond to support their IT workforce. For the 32 nd year, Computerworld ...

Last week, Microsoft released the November monthly update for Windows 11, which fixed a bug that kept Task Manager open in the background but brought new problems with it. The patch in question is ...

Based on the 1986 Stephen King novel, “It,” the new HBO series sets a disturbing and terrifying tone right from the jump. By Sean T. Collins Full disclosure: This episode made it hard for me to get a ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The last time I spoke about Replimune (REPL) it was with respect to a Seeking Alpha article entitled "Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma." With respect to this ...